Sermorelin Peptide: Exploring its Research Potential

Analogues of growth hormone-releasing hormones are known as Sermorelin or GRF 1-29. It is believed to be the shortest completely functional fragment of GHRH and consists of 29 amino acids, representing the 1-29 fragment from endogenous growth hormone releasing hormone. It measures the release of growth hormone. As an acetate salt of an amidated synthetic […]

Analogues of growth hormone-releasing hormones are known as Sermorelin or GRF 1-29. It is believed to be the shortest completely functional fragment of GHRH and consists of 29 amino acids, representing the 1-29 fragment from endogenous growth hormone releasing hormone. It measures the release of growth hormone.

As an acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ), Sermorelin has been hypothesized to mimic the structure of the 44-amino acid residues found at the end of the naturally occurring human growth hormone-releasing hormone.

Studies suggest it may cause the pituitary gland to secrete more growth hormone. The brain produces Sermorelin Acetate spontaneously to increase the pituitary synthesis of growth hormone potentially. It is a shortened version of a growth hormone-releasing factor (GRF 1-44). The pituitary gland generates growth hormone in large quantities. Consequently, the liver produces more Insulin-Like Growth Factor-1 (IGF-1), a peptide with many theorized practical effects.

Research suggests the liver may convert the increased amount of growth hormone released by the stimulated pituitary gland into insulin-like growth factor-1 (IGF-1) via Sermorelin Growth Hormone (GHRH). A rise in blood IGF-1 levels has been hypothesized to cause the metabolism to speed up and new cells to form in the skeleton and organs.

Several studies have speculated the potential impacts of this peptide, including a possible increase in lean muscle mass, a decrease in body fat, an improvement in bone density, a strengthening of the heart and immune system, and many more. Findings imply that because the pituitary gland produces more growth hormone, the endocrine system ensures that the organism does not produce more growth hormone than it can process by stimulating the pituitary gland with Sermorelin GH-RH.

Some have hailed Sermorelin as a game-changer in the context of growth hormone (GH) research. Since the 1980s, when Dr. Daniel Rudman conducted tests on GH, the hormone’s potential in the context of cell aging has been widely purported. Researchers hint there may have been good reports of increased physiological impact, with animal models examined for fat-to-muscle ratios, skin thickness and suppleness, follicle growth, and bone density. However, Dr. Richard Walker, a cell aging specialist and a leading Sermorelin researcher, delves further into the topic. He suggests that while rhGH is well-known to fight against many of the aging degenerative consequences, such as muscular atrophy and fat gain, the fact that it speeds up the pituitary gland’s aging process has received less attention. This dysfunctional outcome is because it has been theorized to inhibit somatotroph activity via negative feedback in a too-extreme manner. Typically, the pituitary gland receives GHRH and somatostatin, two competing hormones, and the somatotroph releases GH in bursts or episodes.

The somatotroph’s GH also feeds on the brain, regulating GHRH and somatostatin secretion as needed. All parts of the neuroendocrine axis rely on this regulatory network to maintain shape and function. When there are consistently high levels of GH in the blood, it inhibits the production of GHRH and endogenous GH by the somatotroph cells. Another possibility is that the organism perceives what seems to be an overabundance of somatotroph activity due to the high amounts of circulating rhGH, which in turn drives cells to generate somatostatin to boost their production. Negatively, rhGH inhibits the brain’s somatotroph stimulatory regions, and directly, excessive somatostatin inhibits the pituitary cells. When these things happen, they worsen the maladaptive changes that happen naturally over time. Thus, ironically, rhGH may counteract some of the age-related physical changes that aren’t ideal. Still, it appears to speed up the neuroendocrine decline and hormonal homeostasis erosion that causes cell aging.

On the other hand, Sermorelin has been speculated to maintain normal feedback linkages by mimicking the stimulatory action of GHRH on the somatotroph and triggering the pituitary to produce GH naturally and episodically. Under the more balanced impact of somatostatin, this effect is assumed to be caused by Sermorelin’s subtle action of stimulating GH secretion.

Finally, compared to rhGH, Sermorelin has been hinted to have at least three major properties, making it a superior choice for cell age research. Sermorelin does not appear to mimic or speed up the effects of cell aging by causing circulating GH to rise too high and profoundly suppressing somatotroph function through disuse atrophy. Instead, it seems to keep the GH neuroendocrine axis feedback relationships more normal, which might promote more physiological profiles of hormone secretion and production.

Researchers interested in this compound may buy Sermorelin for their study from the highest quality research peptide source, Biotech Peptides.

References

[i] Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999 Aug;12(2):139-57. doi: 10.2165/00063030-199912020-00007. PMID: 18031173.

[ii] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. doi: 10.2147/ciia.2006.1.4.307. PMID: 18046908; PMCID: PMC2699646.

[iii] Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021 Mar;9(5):406. doi: 10.21037/atm-20-6561. PMID: 33842627; PMCID: PMC8033379.

[iv] Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.

[v] Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017 Nov;11(6):1752-1757. doi: 10.1177/1557988317718662. Epub 2017 Aug 22. PMID: 28830317; PMCID: PMC5675260.